

0SBM 1FNQIJHVT 7VMHBSJT " \$BTF XIJDI XBT

Citation:

---

11. Ben Lagha N, Poulesquen V, Roujeau JC, Alantar A, Maman L (2005) Pemphigus vulgaris: a case-based update. *J Can Dent Assoc* 71: 667-672.
12. Prajapati V, Mydlarski PR (2008) Advances in pemphigus therapy. *Skin Therapy Lett* 13: 4-7.
13. Weinberg MA, Insler MS, Campen RB (1997) Mucocutaneous features of autoimmune blistering diseases. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod* 84: 517-534.
14. Scully C, Challacombe SJ (2002) Pemphigus vulgaris: update on etiopathogenesis, oral manifestations, and management. *Crit Rev Oral Biol Med* 13: 397-408.
15. Femiano F, Gombos F, Scully C (2002) Pemphigus vulgaris with oral involvement: evaluation of two different systemic corticosteroid therapeutic protocols. *J Eur Acad Dermatol Venereol* 16: 353-356.
16. Bascones-Martinez A, Munoz-Corcuera M, Bascones-Ilundain C, Esparza\_Gomaz G (2010) Oral Manifestations of Pemphigus Vulgaris: Clinical Presentation, Differential Diagnosis and Management. *J Clin Exp Dermatol Res* 1: 112.
17. Saha M, Bhogal B, Black MM, Cooper D, Vaughan RW, et al. (2014) Prognostic factors in pemphigus vulgaris and pemphigus foliaceus. *Br J Dermatol* 170: 116-122.
18. Darling MR, Daley T (2006) Blistering mucocutaneous diseases of the oral mucosa--a review: part 2. Pemphigus vulgaris. *J Can Dent Assoc* 72: 63-66.
19. Kanwar AJ, De D (2011) Pemphigus in India. *Indian J Dermatol Venereol Leprol* 77: 439-449.